Liu Chaofan, Chen Yanzhu, Chen Yulan, Chen Bin, Xie Guojin, Chen Yi
Department of Intensive Care Unit, Binhaiwan Central Hospital of Dongguan, Guangdong Province, Dongguan City, China.
Dongguan City, China.
SN Compr Clin Med. 2021;3(10):2109-2115. doi: 10.1007/s42399-021-01008-w. Epub 2021 Jul 15.
As more and more studies have shown that venovenous extracorporeal membrane oxygenation (VV-ECMO) improves oxygenation and prognosis of critical patients, VV-ECMO has been frequently used in critical patients for severe acute respiratory distress syndrome (ARDS). Prone positioning (PP) is a postural therapy for ARDS, which permits for better ventilation/perfusion ratio (V/Q) matching, improvement of hypoxemia. Some articles revealed that performing PP during ECMO for refractory respiratory failure is feasible; however, the results obtained were controversial. Therefore, we performed a systematic review to further assess the effects of PP during ECMO for refractory respiratory failure. Six studies with 465 subjects were enrolled. Four articles examined changes of PaO2/FiO2 ratio after PP during VV-ECMO; PaO2/FiO2 ratio improved from 18.5 to 62 mmHg. Our analysis inferred that the PP-ECMO group did not have a significant advantage in survival at discharge (odds risk 1.42, 95% confidence interval 0.92-2.18; p = 0.11) compared with the ECMO group. We found that the PP-ECMO group had a significantly longer duration than the ECMO group (MD 5.37, 95% CI 4.19-6.54, I = 67%, P < .00001). ICU length of stay in the PP-ECMO group was significantly longer than the ECMO group (MD 7.29, 95% CI 4.06-10.52, I = 64%, P < .00001). No unplanned extubation of ECMO was recorded. In conclusion, our review found that performing PP during ECMO for refractory respiratory failure is safe and PP can improve the PaO2/FiO2 ratio, which is in line with the length of PP performed.
随着越来越多的研究表明,静脉-静脉体外膜肺氧合(VV-ECMO)可改善危重症患者的氧合及预后,VV-ECMO已被频繁用于患有严重急性呼吸窘迫综合征(ARDS)的危重症患者。俯卧位通气(PP)是一种针对ARDS的体位治疗方法,可使通气/血流比值(V/Q)匹配更佳,改善低氧血症。一些文章表明,在ECMO期间对难治性呼吸衰竭患者进行PP是可行的;然而,所获结果存在争议。因此,我们进行了一项系统评价,以进一步评估在ECMO期间对难治性呼吸衰竭患者进行PP的效果。纳入了6项研究,共465名受试者。4篇文章研究了VV-ECMO期间PP后动脉血氧分压/吸入氧分数值(PaO2/FiO2)比值的变化;PaO2/FiO2比值从18.5 mmHg提高到了62 mmHg。我们的分析推断,与ECMO组相比,PP-ECMO组在出院时的生存方面并无显著优势(比值比1.42,95%置信区间0.92-2.18;p = 0.11)。我们发现,PP-ECMO组的持续时间显著长于ECMO组(平均差值5.37,95%置信区间4.19-6.54,I² = 67%,P <.00001)。PP-ECMO组在重症监护病房(ICU)的住院时间显著长于ECMO组(平均差值7.29,95%置信区间4.06-10.52,I² = 64%,P <.00001)。未记录到ECMO的计划外拔管情况。总之,我们的综述发现,在ECMO期间对难治性呼吸衰竭患者进行PP是安全的,且PP可改善PaO2/FiO2比值,这与PP的实施时长相符。